New biomarker data from BEXMAB study at EHA2023

Faron Pharmaceuticals Oy  
Faron Announces New Biomarker Data from Phase I/II BEXMAB Study at EHA2023 Hybrid Congress
Bexmarilimab mode of action in AML/MDS supported with durable Clever-1... | June 9, 2023

Related Keywords

Boston ,Massachusetts ,United States ,Jukka ,Lapland ,Finland ,Juha Karttunen ,Sandy Jamieson ,Jo Turner ,Christopher Golden ,Lindsey Neville ,Jenniferc Smith Parker ,Julia Balanova ,David Daley ,Head Of Communications ,Prnewswire Faron Pharmaceuticals Oy ,Congress On ,Faron Pharmaceuticals Oy ,Peel Hunt ,Cairn Financial Advisers ,Faron Pharmaceuticals ,European Hematology Association ,Consilium Strategic Communications ,Announces New Biomarker Data ,First North ,Chief Medical Officer ,Certified Adviser ,Nasdaq First ,Faro Technologies ,Nc Stock Exchange ,News ,Information ,Press Release ,Aaron ,Pharmaceuticals ,Nnounces ,Few ,Biomarker ,Data ,Rom ,Hase ,Exmab ,Study ,It ,Ha2023 ,Hybrid ,Mode ,F ,Action ,N ,Upported ,Ith ,Urable Faro Us3116421021 ,